On 20 August 2026, Fosun Pharma (Stock Codes: 600196.SH; 02196.HK) announced that FXR0906 (the “Drug”), a liver-targeted small interfering RNA (siRNA) drug for the treatment of hypertriglyceridemia (HTG), has recently completed the first participant dosing in its Phase 1 clinical trial in Chinese mainland.

FXR0906 is a liver-targeted small interfering RNA (siRNA) drug, which can precisely reduce the level of APOC3 through an mRNA silencing strategy, thereby lowering serum triglyceride level in patients with hypertriglyceridemia. FXR0906 is licensed in by the Group, which is granted an exclusive license to research, develop, register, manufacture and commercialize the drug in Chinese mainland, Hong Kong SAR and Macau SAR.

To date, no small interfering RNA drug for the treatment of hypertriglyceridemia has been approved for marketing in Chinese mainland. On 15 July 2026, FXR0906 received approval through the 30-day fast-track review pathway for innovative drug clinical trial applications by the National Medical Products Administration (.NMPA) Registration clinical studies of FXR0906 will be conducted in Chinese mainland, including a Phase 1 bridging study and subsequent clinical studies, designed to evaluate the Drug’s safety, tolerability, pharmacokinetics and preliminary efficacy in Chinese patients with HTG. The completion of the first participant dosing marks the official launch of clinical development of this innovative therapy in China.

HTG is a common dyslipidemia. According to statistics, the prevalence of HTG (TG≥2.3 mmol/L, approximately 200 mg/dL) in China is approximately 15%, and the number of patients with severe hypertriglyceridemia (sHTG, TG≥5.7 mmol/L, approximately 500 mg/dL) is approximately 10 million. HTG is a risk factor for atherosclerotic cardiovascular disease (ASCVD) and acute pancreatitis. Currently available TG-lowering drugs (such as fibrates, omega-3 fatty acids, and nicotinic acid) have limited efficacy or safety concerns, leaving a significant unmet clinical need. The APOC3‑targeted siRNA therapy is expected to bring a new treatment option for the broad HTG patient population in China, leveraging advantages such as long‑acting effect, convenience, and safety.

The first participant dosing of FXR0906 represents a key R&D milestone for Fosun Pharma in the siRNA field, and marks another tangible progress in executing the Company's innovation‑driven strategy. It will further strengthen the Company's innovative pipeline in the cardiovascular and metabolic therapeutic areas, and accelerate the delivery of more accessible and effective treatment options for patients in China.